Zacks Research Comments on Perrigo’s Q2 Earnings (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) – Equities researchers at Zacks Research lowered their Q2 2027 EPS estimates for Perrigo in a report issued on Thursday, March 19th. Zacks Research analyst Team now expects that the company will post earnings of $0.55 per share for the quarter, down from their prior estimate of $0.71. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s FY2028 earnings at $2.59 EPS.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group reduced their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Argus raised shares of Perrigo to a “hold” rating in a research note on Wednesday, January 14th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Perrigo currently has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Trading Down 4.2%

PRGO opened at $9.25 on Friday. Perrigo has a one year low of $9.23 and a one year high of $28.43. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63. The business has a 50 day simple moving average of $13.29 and a two-hundred day simple moving average of $16.11. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -0.90, a PEG ratio of 1.16 and a beta of 0.41.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.93 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 12.5%. The ex-dividend date of this dividend is Monday, March 2nd. Perrigo’s payout ratio is currently -11.28%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRGO. Corient Private Wealth LLC bought a new stake in Perrigo in the fourth quarter worth $283,000. Alpine Global Management LLC bought a new position in shares of Perrigo during the fourth quarter valued at $181,000. Aristides Capital LLC purchased a new position in shares of Perrigo in the 4th quarter worth about $212,000. T. Rowe Price Investment Management Inc. raised its position in shares of Perrigo by 35.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,386,111 shares of the company’s stock worth $19,295,000 after purchasing an additional 363,501 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Perrigo by 134.2% in the 4th quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock worth $63,230,000 after purchasing an additional 2,602,724 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.